A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants
Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease
Speaker:
Associate Professor B. Rocca (Casamassima, IT)
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding
Speaker:
Associate Professor M. Holinstat (Ann Arbor, US)
Aspirin therapy on prophylactic anticoagulation for hospitalized patients with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry.